A report on a randomised trial using to relieve peanut allergies in children was published in the Lancet today and received extensive publicity
Allergy to peanuts is an increasingly common and important medical disorder, affecting 0·5–1·4% of children in high-income countries. An article published in The Lancet reports the results of the STOP II trial, a two-step, phase 2, unmasked, randomised controlled crossover trial assessing the efficacy of peanut oral immunotherapy (OIT) in 99 children aged 7–16 years. The study found that after 6 months of OIT, 84–91% of the children could safely tolerate daily ingestion of 800 mg of peanut protein, at least 25 times as much peanut protein as they could before the therapy.
Authors: Katherine Anagnostou , Sabita Islam , Yvonne King , Loraine Foley , Laura Pasea Simon Bond ,Chris Palmer , John Deighton , Pamela Ewan, Andrew Clark
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)62301-6/fulltext
